Original Article



How to Cite

Khan, K., Ansari, A., Qureshi, S., & Hassan, Z. (2020). POSTERIOR REVERSIBLE ENCEPHALOPATHY SYNDROME IN CANCER PATIENTS. Annals of Allied Health Sciences, 6(2). Retrieved from


OBJECTIVE: To determine the demographic, clinic-radiological characteristics, the outcomes and close association of chemotherapeutic agents causing Posterior reversible encephalopathy syndrome (PRES) in cancer patients.
METHODS: A retrospective study was conducted at the Shaukat Khanum Memorial Cancer Hospital & Research Centre. Data of the cancer patients who developed PRES from June 2008 to June 2018 was retrieved. A total of 32 patients’ were identified and the pertinent information was recorded in predesigned proforma which included information on demographics, clinical features, drug use, management and outcome. SPSS version 20 was used for simple descriptive analysis.
RESULTS: Of the total 32 patients, 20 (62.5%) were male. Out of total subjects, the diagnosis in majority of cases was lymphoma (n=13, 40.6%). oOher diagnoses included leukemia (n=9, 28.12%), 3 (9.37%) patients had germ cell tumor and 2(6.25%) had rectal carcinoma. All the patients received chemotherapy prior to developing PRES. Half of the patients (50%) received vincristine. Most common clinical presentation was seizures (59.37%); hypertension in 11 (34.37%) patients. 23 patients (71.87%) recovered completely from PRES while 6 patients (18.75%) had partial resolution.

CONCLUSION: In the study, we observed the characteristics of PRES in cancer patients and a close association of chemotherapeutic agents causing PRES.

Original Article

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit